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Abstract 
Purpose: To develop rosuvastatin calcium-loaded self-nanoemulsifying powder for improved oral 
delivery of the drug. 
Methods: Solubility study was carried out in different oils, surfactants and co-surfactants. Based on the 
solubility study, liquid formulations were prepared using LAS/Capryol 90: Maisine 35-1 as oil phase and 
Tween 20 with Lutrol E400 as surfactant mixture (Smix). The liquid formulations were adsorbed onto 
Aerosil 200 in a ratio of 1: 0.25 % w/w to convert them into a solid form. The formulations were 
evaluated for globule size, zeta potential, and emulsion properties. Transmittance study, scanning 
electron microscopy, and in-vitro dissolution studies were carried out. Biochemical studies were carried 
out using a triton-induced hyperlipidemia model in Wistar rats. 
Results: The developed formulations exhibited some desirable characteristics of self-emulsifying 
systems with nano-sized globules in the range 119.8 to 228.9 nm, rapid emulsification in approximately 
60 s and transmittance of close to 100 %. In-vitro dissolution studies on the developed formulations 
indicate a 4-fold increase in drug release in 10 min, compared to the pure drug (ROC) while 
pharmacodynamic data showed significant improvement in oral bioavailability compared to the pure 
drug. 
Conclusion: The developed formulation containing the oils, LAS and combination of capryol 90 with 
Maisine 35-1, has the capability to improve the solubility and bioavailability of rosuvastatin calcium when 
formulated as a self-nanoemulsifying product. 
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Rosuvastatin calcium (ROC) is a synthetic lipid-
lowering agent used for oral administration. The 
IUPAC name of ROC is his [(E)-7-4(4-
flurophenyl)-6-isoproyl-2 [methyl (methyl sulfonyl) 
amino] pyrimidin-5-yl] (3 R, 5 S)-3-5-
duhydroxyhept-6-enoicacid] calcium salt], which 
is slightly soluble in water. The available statins 
have extensive first-pass metabolism [1]. First 
pass hepatic metabolism is responsible for the 
poor bioavailability of ROC. Various approaches, 
includes solid dispersion [2], complexation [3], 
have been reported to overcome solubility and 
bioavailability problems. There is increased 
interest in the development of emulsion type of 
dosage forms; lipid-based self-micro emulsifying 
drug delivery system (SMEDDS) is considered to 
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be promising technology to improve  rate and 
extent of absorption of poorly or slightly water 
soluble drugs to improve bioavailability [4,5]. 
  
SMEDDS is defined as isotropic mixtures of 
natural or synthetic oils, surfactants, one or more 
hydrophilic solvents and co-solvents/surfactants 
that have a unique ability of forming fine oil-in-
water (o/w) micro emulsions upon mild agitation 
followed by dilution in aqueous medium and 
formed emulsion have particle size in the range 
of 1 to 200 nm [6,7].  Thus, for drugs with 
solubility and bioavailability issues, these 
systems may offer the advantages of 
improvement of rate and extent of absorption, 
and thus result in improved bioavailability. Since 
liquid SMEDDS are thermodynamically unstable, 
to achieve improved stability, self-emulsifying 
preparations are generally prepared as a solid 
form [8].  
 
The objective of the study was to prepare a solid 
self-nanoemulsifying dosage form of ROC to 
improve its bioavailability using novel, less costly 







Sefsol 228 (propylene glycol dicaprylate) and 
HCO 40 (PEG 40 hydrogenated castor oil) were 
received as gifts from Barnet Product 
Corporation, NJ. Maisine 35-1 (glycerol 
monolinoleate), Capryol 90 (propylene glycol 
monocapryl), Cremophore RH 40 (polyoxyl 40 
hydrogenated castor oil), Gelucire 44/14 
(saturated polyglcolized glycerides) and Lutrol 
E400 (polyethylene glycol 8) were gifts from 
BASF, India, LAS (PEG-8-caprylic glycerides), 
Transcutol, Lauroglycol 90 (propylene glycol 
monolaurate) were gift samples from Gattefosse 
India P. Ltd. Captex 200, Captex 355 
(triglycerides of caprylic/capric acids) was a gift 
from Abitech WI. Rosuvastatin calcium was 
purchased from Balaji Drugs, Surat, India. Olive 
oil, tween 20, ethyl oleate, propylene glycol and 
castor oil were analytical grade.  
 
Determination of solubility of rosuvastatin 
calcium 
 
Excess amount of ROC was added to 20 ml of 
distilled water. The suspension was equilibrated 
on a mechanical shaker for 24 h at 25 oC   and 
resulting suspensions were filtered through 0.5 
µm Whatman filter paper no. 1. The filtrate (0.1 
ml) was diluted with 10 ml of distilled water to 
determine the dissolved amount of ROC using 
UV visible spectrophotometer (Jasco V-505, 
Japan) at 241 nm. 
 
Determination of rosuvastatin calcium 
solubility 
 
Excess amount of ROC was added to 3 ml of 
different oils (Sefsol 228, HCO 40, Maisine 35-1, 
LAS, ethyl oleate, olive oil, castor oil, Capryol 90, 
Gelucire 44/14), surfactants (Tween 20, 
Lauroglycol and Cremophore RH 40) and co-
surfactants (Lutrol E-400, propylene glycol and 
Transcutol). In each case, the suspension was 
sonicated for 15 min and heated on a water bath 
maintained at 40 °C to allow solubilization of 
ROC. The resulting suspension was agitated on 
a rotary shaker for 24 h to achieve equilibration. 
Thereafter, the suspension was centrifuged at 
4000 rpm for 15 min. The supernatant suitably 
diluted with methanol and the dissolved 
concentration of ROC was determined 
spectrophotometrically at 241 nm. 
 
Identification of micro-emulsion region  
 
From the solubility study, oil, surfactant and co-
surfactant were selected to construct a pseudo 
ternary phase diagram. Maisine 35-1, Capryol 
90, LAS were selected as oil phase; Tween 20 
and Lutrol E 400 were selected as surfactant and 
co-surfactants respectively. From pseudo-ternary 
phase diagram, a stable micro-emulsion zone 
was identified. For the identification of a micro 
emulsion zone, surfactant to co-surfactant ratio 
(Smix) was kept at 1:1. The Smix concentration 
was increased from 1 to 9 by keeping oil phase 
as constant. Oil and surfactant mixture were 
mixed at a ratio of 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 
1:8 and 1:9, respectively. 
 
Furthermore, study was carried out by keeping 
Smix as constant 1:1. Oil and surfactant mixture 
was mixed at a ratio of 1:1, 2:1, 3:1, 4:1, 
respectively [9]. To each of the mixture distilled 
water was added drop wise until the first sign of 
turbidity occurred; the solution was allowed to 
equilibrate and if turbidity changed to a clear 
solution again, excess amount of water was 
added to the observed turbidity. 
 
Preparation of liquid L-SMEDDS and S-
SMEDDS  
 
Based on the phase diagram, oil and Smix ratio 
were selected as vehicle at which wide micro 
emulsion region is observed were selected as 
the vehicle for the formulation of L-SMEDDS. 
ROC was added to the oil phase and sonicated 
for 10 min. To it, surfactant and co-surfactant 
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were added in the proportions shown in Table 1. 
The resultant mixtures were heated over a water 
bath maintained at 40°C for 10 min to facilitate 
solubilization of ROC, and vortexed for 15 min 
until ROC was completely dissolved. 
 
Conversion of Liquid-SMEDDS to Solid-
SMEDDS  
 
Based on the preliminary evaluation, liquid 
formulations containing LAS/ Capryol 90: Maisine 
35-1 with Tween 20: Lutrol E 400 was selected 
for convertion into solid formulation. 
 
S-SMEDD system was prepared by addition of L-
SMEDD to aerosil-200 in 1:0.25 % w/w 
proportion. L-SMEDDS was added drop wise 
onto aerosil-200 in a porcelain dish to get 
uniform distribution of drug and dried at room 
temperature. 
 
Evaluation of L-SMEDDS and S-SMEDDS 
 
Drug content  
 
L-SMEDDS ( L 1 to L 4)  and S-SMEDDS ( S 1 
and S 2) equivalent to 10 mg were dissolved in 
10 ml of methanol in 10 ml volumetric flask 
separately and suitably diluted with methanol to 
determine ROC content at 241 nm 
spectrophotometerically. 
 
Assessment of transmittance and 
reconstitution 
 
L-SMEDDS (L 1 to L 4) and S-SMEDDS (S 1 and 
S 2) formulations (equivalent to 10 mg of ROC) 
were diluted with 100 ml of distilled water 
maintained at 37 ± 2 °C and content was mixed 
gently using magnetic stirrer, and emulsion 
droplet size was observed with respect to time. 
Reconstitution property was evaluated 
qualitatively as good when clear microemulsion 
formed, or bad, if turbid or milky emulsion formed 
after cessation of stirring. For the resultant 
solutions, percent transmittance was determined 
spectrophotometrically at 638.2 nm using distilled 
water as blank.  
Assessment of self-emulsification and 
precipitation 
 
It was performed by drop wise addition of pre-
concentrate (L-SMEDDS), One ml of formulation 
was added to 250 ml of distilled water maintained 
at 37 ± 0.5 °C with stirring of 50 rpm.  
Precipitation was evaluated by visual inspection 
of resulting emulsion after 24 h. Based on 
precipitation study; formulations were 
categorized as Grade A Clear (transparent or 
transparent with bluish tinge), Grade B not clear 
(turbid), Grade C Stable (no precipitation at the 
end of 24 h), Grade D Unstable (showing 
precipitation within 24 h). 
 
Robustness to dilution 
 
L-SMEDDS (L 1 to L 4) and S-SMEDDS (S 1 and 
S 2) formulations (equivalent to 10 mg of ROC) 
were added to 100 ml of distilled water. The 
resulting solutions were observed for phase 
separation for 12 h and 24 h. 
 
In vitro dissolution studies of L-SMEDDS and 
S-SMEDDS 
 
In-vitro dissolution study was carried out using 
USP type II apparatus operated at 50 rpm. L-
SMEDDS and S-SMEDDS containing 10 mg 
equivalent of ROC and plain ROC were filled in 
size 0 capsule shells. The capsule was added to 
900 ml of distilled water as dissolution medium 
maintained at 37± 0.5 °C.  Aliquots (10 ml) were 
withdrawn at predetermined time intervals for 60 
min and analyzed for dissolved ROC content 
spectrophotometrically at 241 nm.   
 
Particle size and zeta potential measurement 
 
One ml (Equivalent to 10 mg) of L-SMEDDS 
containing LAS, Capryol 90: Maisine 35-1 and 10 
mg equivalent of S-SMEDDS containing LAS, 
Capryol 90: Maisine 35-1 were diluted/ 
reconstituted with 100 ml of distilled water. 
 


















L 1 1000 15 - - - 21 21 
L 2  1000 - 15 - - 25 25 
L 3 1000 - - 15 - 21 21 
L 4  1000 - - - 48 11 11 
S 1 1000    48 11 11 
S 2 1000   15 - 21 21 
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The resulting emulsions were subjected to 
determination of globule size and zeta potential 
respectively using malvern zetasizer. 
 
Scanning electron microscopy 
 
The surface morphology of S-SMEDDS 
containing LAS as well as plain ROC powder 
were investigated by S-4100 scanning electron 
microscope ( S-4100 Hitachi, Japan) at 500 X at 




The protocol of the animal study was approved 
by the institutional animal ethical committee 
(IAEC Protocol Approval no. 1036/a/07/ 
CPCESA/IAEC/12-13/E-4). The animals were 
handled and maintained as per the guidelines 
provided by Committee for the Purpose of 
Control and Supervision on Experiments on 
Animals, and also Organization for Economic Co-
operation and Development (OECD) guidelines 
were adhered to the study [10].  
 
The test sought to compare the lipid lowering 
potential of ROC in L-SMEDDS and S-SMEDDS 
formulations. Triton-induced hyperlipidemia 
model in Wistar rats was used. The lipid lowering 
potential of plain ROC was compared with L-
SMEDDS and S-SMEDDS formulations.  
 
The animals were divided into seven groups of 
six animals each as follows: Group I - normal, 
Group II - control, Group III - L-SMEDDS 
containing Maisine 35-1: Capryol 90 as oil (L 3), 
Group IV - L-SMEDDS containing LAS as oil (L 
4), Group V - plain ROC, and Group VI - S-
SMEDDS containing Maisine 35-1: Capryol 90 (S 
2), and Group VII - S-SMEDDS containing LAS ( 
S 1).  
 
Triton X 100 (100 mg/kg) was administered 
intraperitoneally to each animal. Blood samples 
were withdrawn after 72 h after triton injection by 
retro orbital route under light ether anesthesia 
and analyzed for total cholesterol (TC), total 
triglycerides (TG), high density lipoprotein (HDL), 
low density lipoprotein (LDL) and very low 
density lipoprotein (V-LDL) using a diagnostic kit 
provided by Accozyme (India).  
 
After that dose equivalent to 10 mg/kg were 
administered to groups I, II to VII respectively. 
The blood samples were withdrawn after 24 h 
and analyzed for TC, TG, HDL and V-LDL 
concentration. The comparison was carried out 
between the control and test groups [11]. 
 
Statistical analysis  
 
All values were expressed as a mean ± standard 
deviation (SD, n = 3). Comparison between the 
groups was made by one-way analysis of 
variance (ANOVA) followed by Turkey’s test 
using Graph Pad Instat version 2008. Differences 





Solubility of rosuvastatin calcium 
 
The solubility of ROC was 0.32 mg/ml in distilled 
water.  
 
Solubility of rosuvastatin calcium in various 
liquids 
 
Maisine 35-1, Capryol 90 and LAS showed 
highest solubilizing capacity for rosuvastatin 
calcium (Table 2). 
 
Table 2: Solubility of rosuvastatin calcium in different 




Maisine 35-1 57.43 
Capryol 90 27.33 
LAS 44.22 
Gelucire 44/14 18.34 
Sefsol 228 0.40 
HCO 40 8.56 
Castor oil 0.78 
Olive oil 7.08 
Ethyl oleate 1.30 
Captex 200 0.049 
Captex 355 0.21 
 
Among surfactants, Tween 20 showed highest 
solubility (32.15 mg/ml) whereas solubility in 
lauroglycol (11.72 mg/ml) and Cremophore RH 
40 (6.16 mg/ml) was found to be insignificant. 
Among co-surfactants, Lutrol E-400 showed 
highest solubility of 75.59 mg/ml whereas 
solubility in transcutol and propylene glycol was 
found to be 68.65 mg/ml and 23.72 mg/ml 
respectively.  
 
Identification of micro-emulsion zone 
 
Self-microemulsifying system form fine oil in 
water emulsion upon gentle agitation when 
added to aqueous medium. Surfactant and co-
surfactant gets preferentially adsorbed at 
interface, reducing the interfacial energy as well 
as providing mechanical barrier for coalescence.  
Kulkarni et al 




Figure 1: Pseudo-ternary phase diagrams. A = Maisine 35-1, B = LAS, C = Capryol 90, D = Capryol 90: Maisine 
35-1 as oil phase with Tween 20 and Lutrol E 400 as surfactant and co-surfactant at Smix ratio of 1:1 (mean n = 
3) 
 
As seen from the ternary plot (Figure 1), LAS 
gave a wider microemulsion region as compared 
to Capryol 90 and Maisine 35-1. Combinations of 
Capryol 90 and Maisine 35-1 resulted into 
increased oil concentration as that of individual 
oil. Thus LAS and Capryol 90: Maisine 35-1 were 
preferred vehicle with Tween 20 and Lutrol E 400 
as surfactant and co-surfactant, respectively, for 
development of formulation. Based on the 
pseudo ternary phase diagram formulation were 
selected which has less % w/w concentration of 
Smix and greater % w/w of oil phase.    
 




The drug content of all the formulation was in the 
range of 95 to 105 %.  
Transmittance of L-SMEDDS and S-SMEDDS, 
and reconstitution of S-SMEDDS 
 
The transmittance values of L3, L4, S1 and S2 
formulation above 90 % confirming the self-
nanoemulsifying eficiencey of SMEDDS (Table 
3). The reconstitution of solid formulations was 
found to be spontaneous micro emulsification 
upon stirring and it was observed within 60 sec 
upon reconstitution and no sign of precipitation 
and milky appearance for the formed emulsion. 
 
Self-emulsification and precipitation 
assessment 
 
Among the liquid formulations L 1 to L 4, 
formulations L 3 and L 4 exhibited grade A type 
 
Table 3: Drug content and transmittance of L-SMEDDS and S-SMEDDS (Mean, n = 3) 
 
Test Parameters SMEDDS 
L1  L2  L3 L4 S1 S2 
Drug Content* 98.24 99.26 99.38 100.23 100.13 99.23 
Percentage of  
Transmittance* 86.29 87.12 90.34 99.12 98.23 96.29 
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of emulsion with self-emulsification time less than 
1 min, whereas L 1 and L 2 formulation were 
categorized as grade D. 
 
Robustness to dilution 
 
No phase separation was observed for 
preparations L 3, L 4, S 1, S 2 at the end of 24 h 
in distilled water whereas L 1 and L 2 
formulations showed precipitation after 12 h. 
 




Figure 2: In-vitro dissolution profile. ◊ = plain ROC, ● 
= L 1 Formulation, + = L 2 formulation, ■ = l 3 
formulation, □ = l 4 formulation, ◊ = s 1 formulation, ▲ 
= s 2 formulation (mean ± SD, n = 3) 
 
The dissolution study showed that plain ROC 
showed poor release profile when compared to 
L-SMEDDS and S-SMEDDS. At the end of 60 
min, 40 % of the drug was dissolved whereas 
more than 90 % drug was dissolved in distilled 
water from L-SMEDDS and S-SMEDDS 
formulations containing LAS and Capryol 90: 
Maisine 35-1 as oil (Figure 2).  
 
Globule size and zeta potential  
 
For L3, L 4, S 1 and S 2 had z-average globule 
size diameter of 146.1, 119.8, 213.2 and 228.9 
nm, respectively. Zeta potential of the 
formulations was found to be -4.93, -9.14, - 8.06 
and -11.8 respectively. As L 1 and L 2 were 
categorized as unstable formulation and 
categorized as grade D formulation so they are 
excluded from the study. 
 
Morphology of ROC and S-SMEDDS 
 
The SEM micrograph of ROC and S-SMEDDS 
containing LAS were shown in Figure 3. The 
micrograph of Plain Rosuvastatin calcium 
appeared as crystalline (Figure 3, Part X). The 
SEM images of solid SMEDDS showed well-
separated particles with no agglomeration 




Triton is a non-ionic detergent that inhibits 
lipoprotein lipase; therefore it raises levels of 
serum lipids in experimental animals. A single 
injection of triton (100 mg/kg, i.p.) elevated TC, 
TG, LDL and V-LDL levels 2-fold, respectively, 
compared with the untreated group, whereas 
high density lipoprotein level decreased by up to 
50 % in all groups, compared to an untreated 
control group (p > 0.05, Table 4).  
 
At the end of 24 h of dosing, reduction in TC, TG, 
LDL and V-LDL levels was observed in all groups 
except normal group. Formulations containing 
LAS as oil showed greater reduction in elevated 
level of TC, TG, LDL and VLDL (p > 0.05, Table 
4) compared to the formulations containing 




        Figure 3: Scanning electron micrograph of ROC (X) and S-SMEDDS containing LAS (Y) 
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Table 4: Blood TC, TG, HDL, LDL, V- LDL levels of groups after 72 h of Triton injection 
Group Treatment TC TG HDL LDL VLDL 
I Normal 69.79±3.31 126.75±4.2 34.39±1.14 82.84±2.83 28.66±1.91 
II Control 131.77±2.6 184.41±8.8 17.34±2.26 139.68±2.31 75.16±4.92 
III L 3  129.46±3.02 188.69±4.92 17.87±2.01 138.29±2.54 70.32±4.68 
IV L 4 132.04±3.62 196.15±4.49 16.8±2.4 142.66±3.17 73.43±3.86 
V ROC 132.47±2.45 193.19±3.15 17.54±5.45 138.7±0.89 74.97±0.48 
VI S 2 133.18±6.28 187.59±4.79 18.72±1.99 139.1±2.72 74.46±3.87 
VII S 1 130.72±3.7 193.63±5.67 19.19±2.94 137.76±4.79 74.97±4.62 
 
Table 5: Blood TC, TG, HDL, LDL, V- LDL levels of groups after 24 h of administration of ROC dose 
Group Treatment TC TG HDL LDL VLDL 
I Normal 77.81±2.86 120.86±3.48 35.64±2.78 75.31±4.93 25.87±2.41 
II Control 131.51±2.47c 174.3±8.21c 16.24±1.9c 153.72±4.77c 64.47±2.01c 
III L 3 75.86±3.82f, l 120.8±2.92, I, l 39.01±1.3s5f 92.81±6.09 f, K 25.76±2.18f, k 
IV L 4 62.57±3.06 f, l 114.53±2.82f, l 39.44±5.02 f 77.72±7.71 f, l 22.72±1.04 f, k 
V ROC  108.69±5.5e 144.32±3.9 e 36.03±2.85e 120.72±2.83e 45.45±6.13e 
VI S 2 80.56±2.62 f, l 122.2±2.9 f, I, l 38.5±4.16 f 93.14±6.00 f, l 26.45±2.89 f, k 




All formulations of liquid and solid nano-
emulsifying system with ROC gave stable clear 
micro emulsion region.  
 
Drug content, which was in the range of 95 to 
105 %, indicates good drug distribution in the 
selected vehicle. Transmittance values, being 90 
to 100 %, indicate the micro emulsion was 
virtually transparent. With regard to 
emulsification, precipitation and robustness to 
dilution, precipitation was observed within 24 h 
for L 1 and L 2 formulations, and this may be 
attributed to the high concentration of surfactants 
in the formulations, indicates formulations are not 
stable. On the contrary, for L 3, L 4, S 1 and S 2 
formulations, no precipitation was observed for 
24 h. It indicates developed formulations were 
stable. Rapid reconstitution is required for the 
rapid absorption of drug from gastrointestinal 
environment. The solid formulations S 1 and S 2 
showed rapid emulsification time of < 90 sec, 
which may lead to improved absorption of ROC 
from gastrointestinal tract since the drug is 
available in submicron size.  
 
In-vitro dissolution data showed improvement in 
ROC solubility for all formulations compared with 
plain ROC. This may be attributed to increase in 
effective surface area through reduction in the 
mean diameter of globule size. 
 
Globule sizes of formulations were in nano-meter 
range for formulations L 3, L 4, S 1 and S 2. The 
globule size of the emulsion is an important 
factor in self-emulsification process because it 
determines rate and extent of drug dissolution 
and absorption of drug. The charge on the 
droplet is the property determined for 
assessment of absorption. The zeta potential for 
the L 3, L 4, S 1 and S 2 is negative; it is 
because of presence of fatty acids, it confirms 
formed emulsion is nano emulsion and was 
stable. The reported value of formulations was in 
negative between -4.93 to -11.8. The absolute 
value of zeta potential was lower than those 
values reported in the literature. This might be 
attributed to tween 20 and lutrol E 400, non-ionic 
surfactants which decreases the electrostatic 
repulsion between the particles and sterically 
stabilizes the system by forming a coat around 
their surface [12]. The SEM micrograph showed 
crystalline nature of ROC. It is not observed in 
solid SMEDDS micrograph suggesting that the 
drug is completely solubilized in a solid 
SMEDDS. 
 
Clinical studies have demonstrated that ROC is 
the most effective drug in reducing low-density 
lipoprotein cholesterol [13]. 
 
Statins also have beneficial effects on other lipid 
parameters, including increase in high-density 
lipoprotein cholesterol levels and decrease in 
triglyceride levels, and are predominantly 
metabolized by cytochrome P450 [14]. Mixture of 
Capryol 90: Maisine 35-1 and LAS as oil phase 
respectively has the capability to minimize 
variability in absorption as well as to avoid first 
pass metabolism of ROC as it could produce 
more uniform drug concentration in the systemic 
circulation and avoids first pass metabolism, 
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An optimized self-nanoemulsifying formulation 
consisting of a mixture of Capryol 90: Maisine 
35-1/ LAS as the oil phase with Tween 20: Lutrol 
400 as surfactant exhibits spontaneous 
emulsification properties. The formulation shows 
better in-vitro release profile as well as superior 
lipid-lowering potential than plain ROC. 
Futhermore, Aerosil 200 is an effective carrier 
with high drug loading capacity for the 
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